Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$5.55 USD
-0.17 (0.04%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value A Growth C Momentum C VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
MRNANegative Net Change BMYNegative Net Change LXRXNegative Net Change CLVSPositive Net Change
biotechs earnings
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
BIIBNegative Net Change ALXNNegative Net Change AZNNegative Net Change CLVSPositive Net Change
biotechs
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
AZNNegative Net Change PFEPositive Net Change GSKPositive Net Change CLVSPositive Net Change
biotechs
Company News for Dec 22, 2020
by Zacks Equity Research
Companies in the news are: LESL, RP, AJRD, CLVS
RPNegative Net Change CLVSPositive Net Change AJRDNegative Net Change LESLNegative Net Change
aerospace medical
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint
by Zacks Equity Research
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
MRKPositive Net Change GSKPositive Net Change BMYNegative Net Change CLVSPositive Net Change
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
CLVSPositive Net Change
medical
Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CLVSPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
BMYNegative Net Change EBSNegative Net Change CLVSPositive Net Change MGENNegative Net Change
biotechs
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CLVSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLVSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting
by Zacks Equity Research
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
AZNNegative Net Change MRKPositive Net Change GSKPositive Net Change CLVSPositive Net Change
pharmaceuticals
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
CLVSPositive Net Change
biotechs medical
Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CLVSPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
BMYNegative Net Change EBSNegative Net Change HZNPNegative Net Change CLVSPositive Net Change
biotechs earnings
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CLVSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLVSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Clovis (CLVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CLVSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
CLVSPositive Net Change
medical
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
by Zacks Equity Research
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
MRKPositive Net Change GSKPositive Net Change BMYNegative Net Change CLVSPositive Net Change
biotechs
Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CLVSPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
by Zacks Equity Research
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change CLVSPositive Net Change
pharmaceuticals
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
PFEPositive Net Change MRKPositive Net Change GSKPositive Net Change CLVSPositive Net Change
biotechs
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CLVSPositive Net Change
biotechs
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
AZNNegative Net Change GSKPositive Net Change BMYNegative Net Change CLVSPositive Net Change
biotechs earnings
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
CLVSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank